SZARŁOWICZ, Jakub, MAZUR, Michał, WAZ, Dorota, GOLISZEK, Zofia, SOBEK, Karolina Łucja, TABIN-BARCZAK, Wiktoria, SOKOŁOWSKA, Aldona, FIKAS, Klaudia, CHWALISZEWSKI, Kamil and SAMUŁA, Sebastian. Theophylline Revisited. Mechanisms, Challenges, and New Horizons. Quality in Sport. 2025;37:57009. eISSN 2450-3118.
https://doi.org/10.12775/QS.2025.37.57009
https://apcz.umk.pl/QS/article/view/57009

The journal has been 20 points in the Ministry of Higher Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Higher Education and Science of 05.01.2024. No. 32553.
Has a Journal's Unique Identifier: 201398. Scientific disciplines assigned: Economics and finance (Field of social sciences); Management and Quality Sciences (Field of social sciences).
Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 r. Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398.
Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych).

The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 14.12.2024. Revised: 02.01.2025. Accepted: 02.01.2025 Published: 02.01.2025.

Theophylline Revisited. Mechanisms, Challenges, and New Horizons

Jakub Szarłowicz,
Medical Center in Łańcut, Poland
Ignacego Paderewskiego 5, 37-100 Łańcut, Poland
https://orcid.org/0009-0006-8520-9496
szarlowicz.jakub@gmail.com

Michał Mazur,
University of Rzeszów
al. Tadeusza Rejtana 16C, 35-310 Rzeszów, Poland
https://orcid.org/0009-0007-3840-4325
michalmazur1998@gmail.com

Dorota Waz
Medical Center in Łańcut, Poland
Ignacego Paderewskiego 5, 37-100 Łańcut, Poland
https://orcid.org/0009-0004-7484-9231
dorota.waz1@gmail.com

Zofia Goliszek
Medical Center in Łańcut, Poland
Ignacego Paderewskiego 5, 37-100 Łańcut, Poland
https://orcid.org/0009-0005-9881-5754
goliszek1489@gmail.com

Karolina Łucja Sobek
Medical Center in Łańcut, Poland
Ignacego Paderewskiego 5, 37-100 Łańcut, Poland
https://orcid.org/0009-0000-2551-0515
karolinasobek46@gmail.com

Wiktoria Tabin-Barczak
University of Rzeszów
al. Tadeusza Rejtana 16C, 35-310 Rzeszów, Poland
https://orcid.org/0009-0003-8333-8428
wiktoria2509@gmail.com

Aldona Sokołowska
Provincial Clinical Hospital No. 2 named after saint Jadwiga the Queen in Rzeszów,
Lwowska 60, 35-301 Rzeszów
https://orcid.org/0009-0006-8723-2593
aldonasokolowskaa@gmail.com

Klaudia Fikas,
University of Rzeszów
al. Tadeusza Rejtana 16C, 35-310 Rzeszów, Poland
https://orcid.org/0009-0008-1976-2941
fikasklaudia9@gmail.com

Kamil Chwaliszewski,
University of Rzeszów
al. Tadeusza Rejtana 16C, 35-310 Rzeszów, Poland
https://orcid.org/0009-0003-7239-3122
chwaliszewskikamil@gmail.com

Sebastian Samuła
Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin,
Aleja Kraśnicka 100, 20-718 Lublin, Poland
https://orcid.org/0009-0008-8915-4263
sebastian.s94424@gmail.com

Corresponding author: Jakub Szarłowicz, szarlowicz.jakub@gmail.com

Abstract

Introduction and Purpose

Theophylline, used for over a century in asthma and COPD treatment, provides anti-inflammatory and bronchodilatory effects via phosphodiesterase inhibition and adenosine receptor antagonism. This review examines its mechanisms, clinical uses, and emerging applications.

Materials and Methods
A detailed analysis of 23 peer-reviewed studies from scientific databases, including PubMed, focused on theophylline's pharmacokinetics, pharmacodynamics, clinical safety, and novel applications in areas such as immunomodulation, metabolic disorders, and regenerative medicine.
Results
Theophylline shows anti-inflammatory effects, mitochondrial support, and modulation of key pathways (e.g., PI3K/Akt, NF-κB). It demonstrates potential in COVID-19-related ARDS, promoting muscle regeneration, and treating infertility. However, its narrow therapeutic index and variability in pharmacokinetics remain significant challenges.
Conclusion
Theophylline remains a cost-effective option in asthma and COPD and shows promise in broader applications like immunomodulation and metabolic disorders. Further research and advanced drug formulations are needed to enhance its safety and therapeutic potential.

Keywords
Theophylline, Asthma, COPD, adenosine antagonist, immunomodulation, mitochondria, COVID-19, anti-inflammatory

Introduction

Theophylline (1,3-dimethylxanthine), used for over a century, remains a cornerstone of pharmacotherapy for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) (22). Its mechanism of action involves phosphodiesterase (PDE) inhibition, leading to increased cyclic AMP levels, and adenosine receptor antagonism, as depicted in Figure 1, contributing to its anti-inflammatory and bronchodilatory effects (23). Theophylline's ability to modulate inflammatory processes and enhance mitochondrial function extends its potential applications beyond respiratory disorders to include metabolic diseases (21, 23).



Figure 1. Tissue damage and hypoxia stimulates adenosine formation in extracellular space by degradation of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) through the action of nucleotidases such as CD39 and CD73. Rapid degradation of adenosine intracellularly occurs by adenosine kinase and adenosine deaminase, after being taken up through sodium-independent nucleoside transporters (equilibrative nucleoside transporter (ENT)). As ticagrelor inhibits the ENT membrane, adenosine accumulates in the extracellular space, leading to adenosine-mediated effects, such as stimulation of lung neuroreceptors, probably through binding to adenosine membrane receptors (A1, A2A, A2B, and A3), and later to interaction with adenylyl cyclase and formation of cyclic adenosine monophosphate (cAMP). Theophylline blockade of adenosine receptors probably explains inhibition of adenosine-mediated effects (21).

The pharmacokinetics of theophylline are characterized by significant variability, influenced by environmental factors such as smoking and drug interactions, necessitating the monitoring of its plasma levels (5, 19). Despite its narrow therapeutic index, low doses of theophylline are well-tolerated and provide effective support in combination therapy for treating COPD and asthma (6, 8).

In recent years, theophylline has been explored in the context of new therapeutic indications, including COVID-19. Its immunomodulatory properties, such as the ability to reduce the production of pro-inflammatory cytokines like IL-6 and TNF-α, may support the treatment of patients with acute respiratory distress syndrome (ARDS) (10). Additionally, theophylline affects cardiovascular functions through adenosine receptor antagonism, which can be beneficial in treating sinus bradycardia in patients with symptomatic sick sinus syndrome (12). New studies also suggest potential benefits of theophylline in muscle regeneration. In vitro studies have shown that theophylline can counteract dexamethasone-induced muscle atrophy by inhibiting signaling pathways associated with ubiquitin ligases, such as MuRF1 and Cbl-b, and modulating the FoxO3a/p38 MAPK pathway (23).

The aim of this article is to present the current state of knowledge regarding the mechanisms of action, clinical applications, and potential new therapeutic indications of theophylline.

Particular emphasis is placed on the molecular basis of its action and the challenges associated with its use in various patient populations.

Mechanisms of Theophylline Action

Pharmacokinetics and Pharmacodynamics

Theophylline exhibits significant pharmacokinetic variability due to hepatic metabolism and dependence on the activity of cytochrome P450 enzymes, particularly CYP1A2. Induction of this enzyme by smoking reduces the drug's half-life, decreasing its effectiveness. Conversely, CYP1A2 inhibitors, such as macrolides or proton pump inhibitors, can increase theophylline levels and the risk of adverse effects (5, 19).

In pediatric populations, theophylline is metabolized more rapidly, necessitating higher doses compared to adults. In contrast, in geriatric patients and individuals with liver or kidney dysfunction, the metabolism slows, increasing the risk of drug accumulation (8). Theophylline's pharmacodynamics are primarily based on its ability to block adenosine receptors (A1 and A2A) and inhibit phosphodiesterases (PDE), leading to increased intracellular cAMP levels, promoting smooth muscle relaxation, anti-inflammatory effects, and improved mitochondrial function (22).

Effects on the Immune and Inflammatory Systems

Theophylline is an immunomodulator, playing a particularly significant role in inflammatory diseases. By inhibiting NF-κB, it reduces the production of pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, while decreasing neutrophil recruitment and Th2 lymphocyte activity in the respiratory tract (10, 8).

Its effects also include reducing reactive oxygen species (ROS), which limits tissue damage during inflammation. In the context of COVID-19, theophylline has been proposed as a potential supportive treatment due to its ability to modulate cytokine storms, potentially preventing the progression of acute respiratory distress syndrome (ARDS) (10).

Additionally, studies suggest that low doses of theophylline may enhance immune responses by increasing histone deacetylase (HDAC2) activity, thereby improving the effectiveness of glucocorticoid therapy (8).

Effects on Metabolism and Cellular Function

Theophylline impacts signaling pathways crucial for cellular metabolism and regeneration. Activation of the PI3K/Akt pathway promotes cell proliferation and repair processes, while modulation of the FoxO3a/p38 MAPK pathway reduces protein catabolism and protects against muscle atrophy (23).

Its effects on mitochondria include membrane stabilization and improved respiratory function, supporting cellular energy homeostasis, particularly during increased energy demands, such as in chronic respiratory diseases (9, 23).

Experimental models have shown that theophylline decreases the activity of ubiquitin ligases, such as MuRF1 and Cbl-b, counteracting glucocorticoid-induced muscle protein degradation. This action makes theophylline a promising agent for supporting tissue regeneration (23).

Therapeutic Applications of Theophylline

Respiratory Diseases

Theophylline, as a phosphodiesterase inhibitor and adenosine receptor antagonist, has long been used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). In asthma, it exhibits anti-inflammatory and bronchodilatory effects, leading to improved pulmonary function and symptom relief. Its ability to activate histone deacetylase (HDAC2) in combination with inhaled corticosteroids (ICS) enables a synergistic anti-inflammatory effect, reducing the need for higher steroid doses and minimizing their side effects (8, 2).

In COPD, theophylline is primarily used in cases resistant to standard treatment. It has been shown to improve respiratory performance by relaxing smooth muscles and reducing airway

inflammation. Moreover, its use decreases the frequency of exacerbations and enhances the quality of life for patients (6, 22).

Additionally, theophylline may support ventilation in advanced COPD patients, particularly those with hypercapnia. Its effects on respiratory centers in the brain increase the body's ability to adapt to hypoxic conditions (3).

Cardiovascular Diseases

Theophylline’s impact on the cardiovascular system is both a therapeutic challenge and an opportunity. Through adenosine receptor antagonism, it exhibits positive chronotropic effects, making it effective in treating sinus bradycardia. Clinical studies have demonstrated its utility as an alternative for patients who do not qualify for pacemaker implantation (12, 14).

As a non-selective adenosine receptor antagonist (A1 and A2A), theophylline plays a critical role in regulating heart function and respiratory muscles. In cases of cardiac rhythm disorders, such as bradycardia caused by spinal cord injuries (SCI), theophylline blocks excessive adenosine receptor activity in the sinoatrial and atrioventricular nodes. This action increases heart rate and prevents asystole, particularly in autonomic disturbances stemming from parasympathetic dominance in acute SCI (12, 14).

In managing bradycardia following acute cervical spinal injuries, theophylline has shown potential as a pharmacological therapy, reducing the need for invasive treatments like pacemaker implantation. For instance, in a seven-year-old patient with cervical spinal cord injury, theophylline significantly improved clinical outcomes and reduced episodes of bradycardia over 74 days. However, pacemaker implantation was ultimately required when symptoms recurred (14).

On the other hand, high doses of theophylline may cause arrhythmias and other side effects due to excessive sympathetic stimulation. Therefore, caution is essential in patients with cardiac conditions, ensuring regular monitoring of serum drug levels (22).

Potential Impact on Ischemic Stroke

Clinical studies have evaluated theophylline’s effects on cerebral perfusion in ischemic stroke. Results suggest that the drug may increase blood volume in the infarct core, indicating its potential to improve perfusion in damaged brain areas. However, the lack of improvement in regions of reversible ischemia (penumbra) highlights the therapeutic limitations of theophylline in brain tissue rescue (11).

Metabolic and Regenerative Diseases

Theophylline demonstrates intriguing properties in treating metabolic disorders. In vitro studies have shown that it can counteract glucocorticoid-induced muscle atrophy by modulating the FoxO3a/p38 MAPK signaling pathways and inhibiting the expression of ubiquitin ligases, such as MuRF1 and Cbl-b (23).

Research on theophylline extracted from Fu Brick tea indicates its ability to inhibit pancreatic lipase, potentially influencing lipid metabolism and reducing adipose tissue. This mechanism involves reducing reactive oxygen species (ROS) production and inflammatory factors in adipocytes while promoting fatty acid oxidation. Additionally, animal models have shown that theophylline can improve mitochondrial function, reduce liver steatosis, and enhance glucose tolerance, making it a potential therapeutic agent for obesity and its related complications (20).

Specific Clinical Cases

In the context of the COVID-19 pandemic, theophylline has been studied as a supportive treatment for patients with ARDS. Its ability to inhibit NF-κB activity and reduce ROS production helps mitigate cytokine storms, potentially preventing severe disease progression (10). Preliminary studies also suggest that theophylline may improve oxygen saturation and support respiratory functions under hypoxic conditions (3).

Additionally, theophylline has been evaluated for postoperative lumbar puncture pain, where its effects on adenosine receptors reduced pain levels in postoperative patients (13).

Effects on Sperm and Fertility

Theophylline positively influences sperm motility by modulating signaling pathways and reducing oxidative stress. In vitro studies have shown that theophylline can counteract biochemical damage caused by environmental pollutants, such as soot particles (9).

Theophylline's use in stimulating primary ovarian follicles opens new therapeutic possibilities for treating fertility issues. This mechanism involves the regulation of PI3K/Akt and FoxO3a signaling pathways, which support the regeneration of reproductive cells (18).

Theophylline and Breastfeeding

Theophylline, a methylxanthine derivative, is one of the primary metabolites of caffeine formed during its hepatic metabolism. It accounts for approximately 10% of caffeine metabolites, with its presence confirmed in human breast milk. Although theophylline concentrations in breast milk are relatively low, they can vary depending on the mother's diet, residence, education level, and lactation stage. Theophylline has a stimulating effect on the central nervous system, though weaker than caffeine. Despite its low levels in breast milk, excessive maternal caffeine intake may have effects on infants. Therefore, it is recommended to limit caffeine consumption during lactation to avoid potential adverse health effects in infants. Theophylline remains a significant example of a biologically active substance influencing both maternal and infant physiology (2).

Theophylline in Olfactology

Theophylline, primarily known for its bronchodilatory and anti-inflammatory properties, has found applications in treating olfactory disorders, including post-viral olfactory dysfunction (PVOD). Studies on theophylline's mechanisms suggest that by inhibiting phosphodiesterases, it increases cAMP and cGMP levels, promoting the regeneration of damaged sensory axons and improving olfactory signal conduction (15).

In the SCENT (Smell Changes and Efficacy of Nasal Theophylline) study conducted on PVOD patients, nasal irrigation with a theophylline-containing solution was evaluated. Results indicated moderate improvement in olfactory-related quality of life compared to the placebo group. Although changes in psychophysical tests, such as the University of Pennsylvania Smell Identification Test (UPSIT), were limited, the theophylline group reported better outcomes in subjective assessments of olfactory changes and quality of life (15).

Pilot studies on intranasal theophylline formulations have shown a lack of significant side effects, making this therapeutic method promising. In an initial study involving 10 patients, 80% reported improved olfactory function after using a nasal spray with theophylline for four weeks. These results were further corroborated in studies on nasal irrigation, which highlight the need for additional research involving higher theophylline doses to achieve more significant therapeutic effects (15).

Role of Theophylline in Specific Patient Groups

Pediatric and Geriatric Patients

The pharmacokinetics of theophylline differ significantly between pediatric and geriatric populations, necessitating precise therapy adjustments. In children, theophylline metabolism is accelerated due to higher activity of cytochrome P450 enzymes, such as CYP1A2. This results in a shorter drug half-life, requiring more frequent or higher doses to achieve effective therapeutic levels. However, children are more susceptible to adverse effects, such as irritability, insomnia, and headaches, making regular monitoring of serum levels crucial (6, 19).

In geriatric patients, the metabolism of theophylline is slowed due to reduced liver and kidney function, leading to prolonged half-life and an increased risk of drug accumulation. Older adults are more vulnerable to the toxic effects of theophylline, including seizures, cardiac arrhythmias, and nausea. Regular monitoring of serum levels and dose adjustments based on individual pharmacokinetic parameters are essential (5, 8).

Patients with Comorbidities

Theophylline poses particular challenges in patients with comorbidities such as liver or kidney failure. In patients with liver failure, the metabolism of theophylline via CYP1A2 is significantly impaired, leading to increased serum levels and a higher risk of adverse effects. Pharmacokinetic models, such as Child-Pugh and MELD scores, are useful in predicting toxicity risk and determining appropriate dosing (5).

Patients with renal failure have difficulty eliminating theophylline metabolites, which may lead to their accumulation and toxicity. Dose adjustments based on creatinine clearance and regular serum level monitoring are recommended (19).

Drug interactions are a critical issue in this patient group. Macrolides (e.g., erythromycin) and proton pump inhibitors can inhibit theophylline metabolism, increasing its serum concentration and toxicity risk. Conversely, antiepileptic drugs and hepatic enzyme inducers may reduce theophylline's therapeutic efficacy (8).

Treatment in Asthma and COPD

Theophylline is widely used in asthma and COPD therapy, particularly as an adjunctive medication. The addition of low-dose theophylline to inhaled corticosteroids (ICS) demonstrates synergistic effects, enhancing anti-inflammatory efficacy. This mechanism involves histone deacetylase 2 (HDAC2) activation, which reduces the expression of pro-inflammatory genes and improves symptom control (6, 8).

In COPD, theophylline improves exercise tolerance, reduces hypercapnia, and decreases exacerbation frequency. Its mechanism of action involves stimulation of respiratory centers in the brain and relaxation of airway smooth muscles. Theophylline may also protect respiratory muscles, which is especially important in advanced stages of the disease (22).

Guidelines for High-Risk Patient Groups

The management of high-risk patients, including children, older adults, and individuals with multiple comorbidities, requires adherence to several essential principles:

1. **Regular monitoring of serum drug levels**: Strict control of theophylline levels minimizes toxicity risk and allows for individualized dosing adjustments (19).
2. **Dose adjustments based on liver and kidney function**: Patients with impaired hepatic or renal function require lower doses and more frequent pharmacokinetic monitoring (5).
3. **Avoidance of drug interactions**: Medications such as macrolides, proton pump inhibitors, and antiepileptic drugs can significantly alter theophylline serum concentrations, necessitating careful evaluation of potential interactions (6, 8).

Adherence to these guidelines enables the effective and safe use of theophylline in treating respiratory and other diseases in patient groups particularly vulnerable to adverse effects.

Limitations and Challenges in Theophylline Use

Narrow Therapeutic Index

Theophylline has a very narrow therapeutic index, making its clinical use challenging. The therapeutic range is 10–20 mg/L, with levels above 20 mg/L considered toxic. Theophylline toxicity can result in severe adverse effects such as seizures, tachycardia, arrhythmias, nausea, and vomiting. Rhabdomyolysis, a rare but life-threatening complication, can lead to acute renal failure in cases of overdose (16).

Pharmacokinetic variability, caused by differences in theophylline metabolism related to age, comorbidities, and drug interactions, further complicates its use. In geriatric patients, reduced liver and kidney function increases the risk of drug accumulation, while in children, faster metabolism requires higher doses to achieve therapeutic effects (19).

Drug Interactions and Overdose

Theophylline is prone to numerous drug interactions. Inhibition of cytochrome P450 enzymes, particularly CYP1A2, by macrolides (e.g., erythromycin), proton pump inhibitors (e.g.,

omeprazole), or antifungal agents increases serum theophylline levels, raising the risk of adverse effects. Conversely, enzymatic inducers like rifampin or antiepileptic drugs (e.g., carbamazepine) accelerate theophylline metabolism, reducing its therapeutic efficacy (4, 19).
Theophylline overdose, often caused by improper dose adjustments or unrecognized drug interactions, can lead to severe complications such as seizures, respiratory arrest, or death. In critical cases, methods such as hemofiltration or hemodialysis are recommended for drug removal, though these require specialized equipment and care (16).

Reduced Efficacy in Long-Term Therapy

Long-term theophylline use may result in tolerance, weakening its therapeutic effects. This mechanism involves the downregulation of adenosine receptors, reducing their sensitivity to the drug. Studies suggest that combining theophylline with inhaled corticosteroids may enhance therapeutic efficacy by activating histone deacetylase 2 (HDAC2), improving inflammation control. However, the effectiveness of this approach is limited and warrants further investigation (8, 22).

Lack of Innovative Drug Formulations

Currently available theophylline formulations, such as immediate-release or extended-release tablets, are insufficient in terms of safety and user comfort. The lack of modern delivery systems, such as nanotechnology carriers or controlled-release systems, limits the potential to improve the drug's safety profile and efficacy. Innovative pharmaceutical technologies could minimize toxicity risks and enhance patient adherence to therapy (22).

Need for Research into New Indications

Theophylline has potential in new therapeutic areas that require further research. In vitro studies have shown that theophylline can counteract glucocorticoid-induced muscle atrophy by modulating signaling pathways such as PI3K/Akt and FoxO3a/p38 MAPK. This action positions theophylline as a promising agent for treating degenerative muscle diseases (23).
Additionally, theophylline has been shown to reduce ROS (reactive oxygen species) production and improve mitochondrial function, which is significant in the treatment of chronic inflammatory and metabolic conditions such as type 2 diabetes and obesity. Its ability to stabilize cellular energy functions opens new directions for research into regenerative therapies (7, 22).

Comparative Analysis of Theophylline Applications in the Context of Modern Therapies

Theophylline vs. Modern Bronchodilators

Despite its long-standing use in the treatment of asthma and COPD, theophylline has been largely supplanted by modern bronchodilators such as long-acting beta-agonists (LABA, e.g., salmeterol, formoterol) and long-acting muscarinic antagonists (LAMA, e.g., tiotropium). These newer drugs exhibit superior efficacy in improving respiratory parameters, such as forced expiratory volume in one second (FEV1), and have a better safety profile. Unlike theophylline, which has a broad, non-selective pharmacological action, LABA and LAMA act directly on specific adrenergic or muscarinic receptors in the airways, minimizing the risk of adverse effects (8, 22).
Theophylline, however, retains an advantage in conditions where inflammation control is critical. Its mechanism of action involves phosphodiesterase inhibition (primarily PDE3 and PDE4) and histone deacetylase 2 (HDAC2) activation, which reduce pro-inflammatory cytokine production and improve responsiveness to corticosteroids. These anti-inflammatory effects are absent in LABA and LAMA, which focus solely on bronchial smooth muscle relaxation (1, 8).
A major limitation of theophylline compared to modern bronchodilators is its narrow therapeutic index, which necessitates regular monitoring of plasma drug levels. Adverse effects such as tachycardia, cardiac arrhythmias, headaches, and nausea are more common with theophylline, restricting its use as monotherapy (6, 22).

Theophylline as a Component of Combination Therapy

Theophylline demonstrates potential in combination therapy, particularly with inhaled corticosteroids (ICS). Adding low-dose theophylline to ICS therapy can improve symptom control in asthma and COPD, especially in patients who respond poorly to steroids. This mechanism involves HDAC2 activation, enhancing the efficacy of corticosteroids by reducing pro-inflammatory gene expression and oxidative stress (1, 8).

Clinical studies, such as TWICS and TASCS, have provided significant data on the use of theophylline combined with ICS in COPD. Results indicate that while theophylline does not always reduce the overall number of exacerbations, it may decrease the frequency of severe exacerbations requiring hospitalization, particularly in patients with higher blood eosinophil levels (8, 17).

In asthma treatment, combining theophylline with ICS may allow for steroid dose reduction while maintaining symptom control. This approach reduces the risk of corticosteroid-related side effects, such as osteoporosis or steroid-induced diabetes. However, due to the potential adverse effects of theophylline, careful monitoring of serum levels is essential (1, 8).

Theophylline in the Context of Cost and Accessibility

In resource-limited medical settings, theophylline continues to play a crucial role as an affordable and widely available drug, especially compared to expensive modern bronchodilators that often require specialized inhalers. Theophylline's oral formulation makes it suitable for use in areas with restricted access to healthcare, rendering it a valuable therapeutic tool in many parts of the world (6, 22).

Social and Economic Significance of Theophylline

Accessibility in Developing Countries

As one of the oldest drugs used in asthma and COPD therapy, theophylline plays a crucial role in developing countries, where access to modern bronchodilators such as LABA and LAMA is limited due to high costs and infrastructure requirements. Theophylline is widely available in oral form, making it more practical in resource-constrained medical environments. It is particularly useful in rural areas where the lack of specialized inhalers restricts the use of other therapies (6, 8).

Studies conducted in Africa and Asia have shown that theophylline is a cost-effective solution for treating COPD associated with biomass smoke exposure, a common issue in households using open fires for cooking. Its use reduces symptom severity, improves quality of life, and lowers hospitalization rates, which is critical in countries with limited access to advanced medical care (6, 22).

Theophylline is also an essential medication in low-income countries where other therapies, such as LABA, are unavailable due to their high costs. It enables symptom control at minimal expense, making it a foundational option for treating chronic respiratory diseases in such regions (8, 22).

Impact on Healthcare Systems

The cost of treatment with theophylline is significantly lower compared to modern therapies, making it more accessible to patients and less burdensome for healthcare systems. Studies in South Africa have demonstrated that even in cases of theophylline toxicity, the hospitalization and treatment costs were lower compared to advanced treatment methods for obstructive pulmonary diseases. This underscores theophylline's role as a critical medication in healthcare systems with limited financial resources (6, 16).

Due to its low price and availability, theophylline reduces the need for more expensive medications and hospitalizations, enabling more efficient allocation of resources within healthcare systems. Economic modeling suggests that treating COPD with theophylline is among the most cost-effective strategies in middle- and low-income countries. The costs per Disability-Adjusted Life Year (DALY) are significantly lower compared to modern

bronchodilators, making theophylline a preferred option in financially constrained settings (6, 8).

In developed countries, despite its limited use, theophylline remains relevant for patients with financial difficulties or those intolerant to modern medications. It also serves as an alternative when access to specialized inhalers is restricted (6, 22).

Conclusion

Theophylline, one of the oldest methylxanthine drugs, remains a vital component of modern pharmacotherapy, both in conventional and emerging clinical applications. This article highlights the extensive capabilities of the drug, focusing on its mechanisms of action, therapeutic applications, and the challenges associated with its use.

Theophylline's primary mechanisms of action include phosphodiesterase (PDE) inhibition, adenosine receptor antagonism, and modulation of signaling pathways such as PI3K/Akt and FoxO3a/p38 MAPK. These mechanisms contribute to its anti-inflammatory, immunomodulatory, and tissue-regenerative properties. In asthma and chronic obstructive pulmonary disease (COPD), theophylline plays a critical role as an adjunctive therapy. It improves respiratory function, reduces inflammation, and decreases the frequency of exacerbations. Additionally, by activating histone deacetylase 2 (HDAC2), theophylline enhances corticosteroid efficacy, allowing for dose reduction and minimizing corticosteroid-related adverse effects.

Beyond its traditional applications in respiratory diseases, research points to theophylline's potential in new clinical indications. It has been used in the treatment of olfactory dysfunction, where its ability to increase cAMP and cGMP levels promotes sensory axon regeneration and improves olfactory function. Studies on fertility disorders have shown theophylline's capacity to enhance sperm motility and regenerate ovarian cells through signaling pathway modulation. Furthermore, its mitochondrial protective effects and ability to reduce oxidative stress open new therapeutic opportunities in managing metabolic diseases such as type 2 diabetes and obesity.

Theophylline has also been applied in postoperative pain management related to lumbar punctures and as supportive therapy in severe COVID-19 cases. Its ability to modulate cytokine storms and reduce reactive oxygen species (ROS) makes it a promising adjuvant in severe inflammatory conditions, such as acute respiratory distress syndrome (ARDS).

Despite its numerous advantages, theophylline poses significant clinical challenges. Its narrow therapeutic index necessitates regular plasma level monitoring, particularly in pediatric, geriatric, and comorbid patient populations, such as those with liver or kidney dysfunction. The drug's susceptibility to numerous pharmacological interactions complicates its use in combination therapy. Moreover, the lack of advanced formulations, such as controlled-release systems, impacts patient compliance and toxicity risks.

From a socio-economic perspective, theophylline plays a crucial role in developing countries, where it serves as a cost-effective alternative to more expensive modern therapies. Its broad availability and simplicity of oral administration enable the treatment of obstructive pulmonary diseases in resource-limited regions. Economic modeling suggests that theophylline therapy is highly cost-effective in improving population health, further emphasizing its global significance.

In summary, despite its age, theophylline remains a drug with a broad spectrum of applications, combining anti-inflammatory, immunomodulatory, and bronchodilatory properties. Its potential in new therapeutic areas, such as tissue regeneration and olfactory dysfunction treatment, requires further clinical investigation. Understanding its mechanisms of action and developing modern pharmaceutical technologies could enhance theophylline's role in contemporary medicine while minimizing associated risks.

Disclosures

Author's contribution

Conceptualization – Jakub Szarłowicz, Dorota Waz, Zofia Goliszek
Formal analysis – Jakub Szarłowicz, Karolina Sobek, Michał Mazur
Investigation – Sebastian Samuła, Wiktoria Tabin-Barczak, Kamil Chwaliszewski
Data curation – Jakub Szarłowicz, Wiktoria Tabin-Barczak, Sebastian Samuła
Writing – rough preparation – Michał Mazur, Zofia Goliszek, Aldona Sokołowska
Writing – review and editing – Dorota Waz, Klaudia Fikas, Kamil Chwaliszewski
Visualization – Aldona Sokołowska, Klaudia Fikas, Karolina Sobek
All authors have read and agreed with published version of the manuscript.

Funding Statement – No applicable.
Institutional Review Board Statement – Not applicable.
Informed Consent Statement – Not applicable.
Data Availability Statement – The authors confirm that the data supporting this study are available in the article's references.
Conflict of Interest – Authors declare no conflict of interest.

References:

1. Bradbury T, Di Tanna GL, Scaria A, et al. Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASCS Trial. *Int J Chron Obstruct Pulmon Dis*. 2022;17:273-282. Published 2022 Feb 5. doi:10.2147/COPD.S339889
2. Purkiewicz A, Pietrzak-Fiećko R, Sörgel F, Kinzig M. Caffeine, Paraxanthine, Theophylline, and Theobromine Content in Human Milk. Nutrients. 2022;14(11):2196. Published 2022 May 25. doi:10.3390/nu14112196
3. Subudhi AW, Evero O, Reitinger J, et al. Combined methazolamide and theophylline improves oxygen saturation but not exercise performance or altitude illness in acute hypobaric hypoxia. *Exp Physiol*. 2021;106(1):117-125. doi:10.1113/EP088461
4. Okada A, Sera S, Taguchi M, Yamada H, Nagai N. Current status and usefulness of therapeutic drug monitoring implementation of theophylline in elderly patients based on a nationwide database study and modeling approach. *Sci Prog*. 2024;107(3):368504241285122. doi:10.1177/00368504241285122
5. Kurata Y, Muraki S, Hirota T, Araki H, Ieiri I. Effect of liver cirrhosis on theophylline trough concentrations: A comparative analysis of organ impairment using Child-Pugh and MELD scores. *Br J Clin Pharmacol*. 2022;88(8):3819-3828. doi:10.1111/bcp.15333
6. Siddharthan T, Pollard SL, Jackson P, et al. Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial. *Trials*. 2021;22(1):213. Published 2021 Mar 16. doi:10.1186/s13063-021-05163-2
7. Tänzler D, Kipping M, Lederer M, et al. Effects of theophylline on ADCY5 activation-From cellular studies to improved therapeutic options for ADCY5-related dyskinesia patients. *PLoS One*. 2023;18(3):e0282593. Published 2023 Mar 3. doi:10.1371/journal.pone.0282593
8. Shuai T, Zhang C, Zhang M, et al. Low-dose theophylline in addition to ICS therapy in COPD patients: A systematic review and meta-analysis. *PLoS One*. 2021;16(5):e0251348. Published 2021 May 24. doi:10.1371/journal.pone.0251348

9. Esmeryan KD, Rangelov I, Chaushev TA. Manipulated sperm motility via soot nanoparticles-induced biochemical alterations in human seminal plasma. *Reprod Biol*. 2023;23(3):100793. doi:10.1016/j.repbio.2023.100793
10. Wall GC, Smith HL, Trump MW, et al. Pentoxifylline or theophylline use in hospitalized COVID-19 patients requiring oxygen support. *Clin Respir J*. 2021;15(7):843-846. doi:10.1111/crj.13363
11. Modrau B, Winder A, Hjort N, et al. Perfusion Changes in Acute Stroke Treated with Theophylline as an Add-on to Thrombolysis : A Randomized Clinical Trial Subgroup Analysis. *Clin Neuroradiol*. 2022;32(2):345-352. doi:10.1007/s00062-021-01029-x
12. Jin IT, Yoon N, Jeong HK, Lee KH, Park HW, Cho JG. Positive chronotropic effects of theophylline and cilostazol in patients with symptomatic sick sinus syndrome who have declined permanent pacing. *Rev Cardiovasc Med*. 2020;21(3):473-480. doi:10.31083/j.rcm.2020.03.22
13. Barati-Boldaji R, Shojaei-Zarghani S, Mehrabi M, Amini A, Safarpour AR. Post-dural puncture headache prevention and treatment with aminophylline or theophylline: a systematic review and meta-analysis. *Anesth Pain Med (Seoul)*. 2023;18(2):177-189. doi:10.17085/apm.22247
14. Karim F, Chang P, Garrison C, Steiner M. Role of Theophylline in Management of Bradycardia Secondary to High Cervical Spinal Cord Injury in a Seven-Year-Old Child: Case Report and a Review of Literature. *Cureus*. 2020;12(10):e10941. Published 2020 Oct 14. doi:10.7759/cureus.10941
15. Lee JJ, Peterson AM, Kallogjeri D, et al. Smell Changes and Efficacy of Nasal Theophylline (SCENT) irrigation: A randomized controlled trial for treatment of post-viral olfactory dysfunction. *Am J Otolaryngol*. 2022;43(2):103299. doi:10.1016/j.amjoto.2021.103299
16. Oxley-Oxland JV, Freercks R, Baker D, Van der Merwe E. The characteristics and costs of severe theophylline toxicity in a tertiary critical care unit in Eastern Cape Province, South Africa. *S Afr Med J*. 2022;112(11):866-870. Published 2022 Nov 1. doi:10.7196/SAMJ.2022.v112i11.16453
17. Jenkins CR, Wen FQ, Martin A, et al. The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial. *Eur Respir J*. 2021;57(6):2003338. Published 2021 Jun 10. doi:10.1183/13993003.03338-2020
18. Zhang W, Gao L, Zhang X, et al. Theophylline derivatives promote primordial follicle activation via cAMP-PI3K/Akt pathway and ameliorate fertility deficits in naturally aged mice. *Int J Biol Sci*. 2024;20(13):5312-5329. Published 2024 Sep 30. doi:10.7150/ijbs.99936
19. Frymoyer A, Van Meurs KP, Drover DR, Klawitter J, Christians U, Chock VY. Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia. *Pediatr Res*. 2020;88(6):871-877. doi:10.1038/s41390-020-01140-8
20. Liu TT, Liu XT, Huang GL, Liu L, Chen QX, Wang Q. Theophylline Extracted from Fu Brick Tea Affects the Metabolism of Preadipocytes and Body Fat in Mice as a Pancreatic Lipase Inhibitor. *Int J Mol Sci*. 2022;23(5):2525. Published 2022 Feb 25. doi:10.3390/ijms23052525
21. Sanmartin-Fernandez M, Zamorano JL. Theophylline for Attenuating Ticagrelor-Related Dyspnea. Teofilina para o Alívio da Dispneia Relacionada ao Ticagrelor. *Arq Bras Cardiol*. 2021;117(1):146-148. doi:10.36660/abc.20201076

22. Montaño LM, Sommer B, Gomez-Verjan JC, et al. Theophylline: Old Drug in a New Light, Application in COVID-19 through Computational Studies. *Int J Mol Sci*. 2022;23(8):4167. Published 2022 Apr 9. doi:10.3390/ijms23084167
23. Yoshioka Y, Imi Y, Kawabata K, Shibata K, Terao J, Miyoshi N. Theophylline Prevents Dexamethasone-Induced Atrophy in C2C12 Myotubes. *J Nutr Sci Vitaminol (Tokyo)*. 2023;69(4):284-291. doi:10.3177/jnsv.69.284